Summit Therapeutics is trading at $14.92, up 5.14%, rebounding after its November 5 close of $14.19.
- No clear November 6 company-specific announcement was identified to explain the gain.
- Summit’s recent Q3 report showed a narrower-than-expected loss per share. The FDA decision date for ivonescimab is November 14; these are relevant context, but do not establish the reason for the move.
- The biotech sector is down, so sector weakness does not explain Summit’s rise.